Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000173 · ClinicalTrials.gov registry record · Phase 3
Memory Impairment Study (Mild Cognitive Impairment Study)
A Phase 3 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 3
- Development phase
NCT00000173 is a Phase 3 study that has completed, run by National Institute on Aging (NIA).
The verdict
NCT00000173, a Phase 3 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
Interventions
- DRUG Donepezil
- DRUG Vitamin E
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-03 |
| Est. Completion | 2004-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000173
The ClinicalTrials.gov registry entry for NCT00000173 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Donepezil is the first listed.
NCT00000173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000173 about?
NCT00000173 is a clinical study titled "Memory Impairment Study (Mild Cognitive Impairment Study)". The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-...
What is the current status of trial NCT00000173?
This trial is currently completed. It is a Phase 3 study. The study started on 1999-03. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00000173?
The interventions under investigation include: Donepezil (DRUG), Vitamin E (DRUG).
Who is sponsoring clinical trial NCT00000173?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.